<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485080</url>
  </required_header>
  <id_info>
    <org_study_id>33431</org_study_id>
    <nct_id>NCT02485080</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1</brief_title>
  <official_title>Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot study is to examine both efficacy and tolerability in patients with
      HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower. The CPT
      score is used to assess the prognosis of chronic liver diseases, as well as the required
      strength and treatment and necessity of liver transplantation. A higher CPT score denotes
      higher necessity of liver transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Key objectives of this study include:

        1. To describe efficacy (SVR) in a special population of patients with chronic hepatitis C
           who are not willing or not candidates for IFN-based therapy.

        2. To describe safety, tolerability, and treatment persistency in this patient population
           with advanced liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn due to lack of resources
  </why_stopped>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virologic response (SVR) HCV RNA PCR &lt;25 IU/mL 12 weeks post-treatment</measure>
    <time_frame>12 weeks after end of treatment or virologic response after liver transplantation, whichever comes first, assessed up to 12 weeks after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events, adverse events grade 3 and above</measure>
    <time_frame>24 weeks while on treatment and 24 weeks after end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>PT-NANBH</condition>
  <arm_group>
    <arm_group_label>Simeprevir + sofosbuvir daily, 24 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <arm_group_label>Simeprevir + sofosbuvir daily, 24 weeks</arm_group_label>
    <other_name>Olysio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <arm_group_label>Simeprevir + sofosbuvir daily, 24 weeks</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Adult 18-72 years

          2. Cirrhosis: defined by stage 4 on biopsy or noninvasive tests or presence of
             splenomegaly and platelet of 130K or lower, or presence of shrunken nodular liver on
             CT or MRI, or presence of varices or encephalopathy or ascites.

          3. HCV genotype 1 or indeterminate and later assessed at Screening and confirmed as
             genotype 1

        Exclusion criteria:

          1. Uncontrolled ascites, uncontrolled hepatic encephalopathy, or uncontrolled
             esophageal/gastric varices

          2. Co-infection with HIV or hepatitis B (HBV)

          3. CPT 7 or above, or MELD &gt;10

          4. Total bilirubin 4.0 mg/dL or above

          5. CrCl (creatinine clearance) &lt; 30 mL/min

          6. Any unstable active medical illnesses.

          7. Active use of illicit substances, alcohol, or smoking.

          8. Any malignancy within last 5 years except for basal cell skin cancer that has been
             adequately treated or HCC within Milan or UCSF criteria, which will be acceptable

          9. Any prior treatment with direct acting antivirals (approved or investigational),
             including HCV protease inhibitors, such as SMV. Patients who received prior treatment
             with SOF, and/or NS5A inhibitors (e.g. ledipasvir or Daclatasvir) can be included in
             this study

         10. Platelet &lt; 30 K/uL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindie H Nguyen, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hcvguidelines.org</url>
    <description>Recommendations for Testing, Managing, and Treating Hepatitis C by the American Association for the Study of Liver Diseases and Infectious Disease Society of America</description>
  </link>
  <link>
    <url>https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf</url>
    <description>SOLVALDI (Sofosbuvir) package insert</description>
  </link>
  <reference>
    <citation>Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 2012 Feb;32 Suppl 1:120-8. doi: 10.1111/j.1478-3231.2011.02714.x. Review.</citation>
    <PMID>22212582</PMID>
  </reference>
  <reference>
    <citation>Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009 Apr;50(4):719-28. doi: 10.1016/j.jhep.2008.11.015. Epub 2008 Dec 29.</citation>
    <PMID>19217183</PMID>
  </reference>
  <reference>
    <citation>Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007 Feb;46(2):206-12. Epub 2006 Oct 20.</citation>
    <PMID>17125876</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mindie H. Nguyen</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

